Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of CNTO 1275 (anti-IL-12p40) in relapsing-remitting multiple sclerosis
2004-000145-38Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Sep 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ustekinumab in multiple sclerosis (MS) (4 arms), sponsored by Janssen Biotech. Primary endpoint: Primary. Started Sep 2004; status: completed.
02
Drugs
ustekinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2004-000145-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000145-38.